Table 5.
AESI | AstraZeneca | Pfizer | Moderna | Janssen |
---|---|---|---|---|
COVID-19 infection | 17 | 3 | 0 | 1 |
Hypersensitivity | 9 | 8 | 1 | 0 |
Arrhythmia | 6 | 7 | 1 | 0 |
Epilepsy | 2 | 1 | 2 | 0 |
Facial paralysis | 1 | 0 | 1 | 0 |
Hypersomnia | 1 | 0 | 1 | 0 |
Myocardial infarction | 0 | 2 | 0 | 0 |
Product administration error | 1 | 0 | 0 | 1 |
Pulmonary embolism | 2 | 0 | 0 | 0 |
Acute myocardial infarction | 1 | 0 | 0 | 0 |
Anaphylactic reaction | 0 | 0 | 0 | 1 |
Atrioventricular block complete | 0 | 1 | 0 | 0 |
Cerebrovascular accident | 0 | 1 | 0 | 0 |
Facial paresis | 1 | 0 | 0 | 0 |
Myocarditis | 0 | 1 | 0 | 0 |
Pericarditis | 0 | 1 | 0 | 0 |
Petit mal epilepsy | 0 | 1 | 0 | 0 |
Platelet count decreased | 0 | 0 | 1 | 0 |
Respiratory arrest | 1 | 0 | 0 | 0 |
Seizure | 0 | 1 | 0 | 0 |
Thrombosis | 1 | 0 | 0 | 0 |
Vasculitis | 1 | 0 | 0 | 0 |
Total | 44 | 27 | 7 | 3 |
AESI adverse events of special interest